EMA Authorised: Brinsupri (Brensocatib monohydrate) — Insmed Netherlands B.V.

View source ↗

Summary

The European Medicines Agency authorized Brinsupri (brensocatib monohydrate) by Insmed Netherlands B.V. for bronchiectasis. This marks EU approval of a new ther…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiectasis

Drugs mentioned

• BRINSUPRI (BRENSOCATIB)

Snippet

Status: Authorised. Therapeutic area: Bronchiectasis;Lung Diseases. MAH: Insmed Netherlands B.V.. Decision date: 18/11/2025